Eurofen

Quick links to important sections

Eurofen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eurofen

Property Description
Active ingredient Carprofen
Form Tablets, Injectable Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Management of inflammation and pain
Origin Synthetic Compound (Propionic Acid Derivative)

What Type of Medicine is Eurofen, and What is its Core Purpose?

Eurofen is a synthetic pharmacological agent whose active substance is Carprofen, officially belonging to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. Structurally, it is derived from propionic acid, classifying it as a Propionic Acid Derivative. This classification is clinically recognized for providing anti-inflammatory, analgesic, and antipyretic actions. The medicine's core purpose is to provide symptomatic relief through its capabilities as an analgesic for pain reduction, an anti-inflammatory agent to limit swelling, and an antipyretic to lower fever. This comprehensive symptomatic action is characteristic of the established use of NSAIDs for these combined effects.

Composition of Eurofen and its Forms

The entire therapeutic activity of this medicine relies exclusively on Carprofen, making it a single-ingredient product with a focused pharmacological profile. While Carprofen was historically used in human medicine, it is currently positioned predominantly for use in veterinary practice. The drug is typically made available in forms suitable for different routes of administration, including preparations for oral ingestion, frequently as tablets, and injectable solutions for parenteral administration. This dual availability provides flexibility for the management of conditions like joint discomfort or post-surgical recovery.

The General Principle of Relief

Eurofen works by modulating the body's inflammatory response, specifically by interfering with the process that creates chemical messengers known as prostaglandins. These lipid compounds are primarily responsible for initiating localized pain and swelling. The interference with this signaling cascade is the underlying principle that enables Eurofen to effectively help manage physical discomfort, swelling, and elevated temperature, which are common symptoms observed during musculoskeletal irritation.

Regulatory References

  1. NSAID Mechanisms, NIH

What side effects are possible with Eurofen?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential effects of this medicine primarily by affected organ system. The most frequently observed adverse reactions are categorized under Gastrointestinal System Disorders, including vomiting, soft stools, and decreased appetite. These effects generally manifest early, often occurring within the first week of treatment, as documented in the official safety information.

While typically reversible, the drug's safety profile notes the potential for serious adverse reactions, although these are officially classified as rare or very rare. These include severe events such as gastrointestinal ulceration and/or perforation, acute renal failure, and idiosyncratic hepatic adverse events (severe liver toxicity). Reactions affecting the Hepato-biliary and Renal and Urinary systems are considered major safety concerns.

Specific safety constraints are documented for certain populations. The medicine is contraindicated for individuals with pre-existing conditions such as cardiac, hepatic, or renal disease, or gastrointestinal bleeding. Furthermore, use is generally avoided in individuals who are dehydrated or those receiving concurrent treatment with other nonsteroidal anti-inflammatory drugs or corticosteroids, due to potential risk elevation. For individuals on long-term treatment, the official safety documentation notes a potentially higher risk of adverse reactions and the need for regular observation.

Overdose and Emergency Response

The official regulatory profile for Eurofen (Carprofen) overdose focuses on severe systemic organ toxicity, which necessitates immediate action. Documented manifestations may include significant gastrointestinal effects such as vomiting, melena (dark or tarry stools), and constipation, alongside signs of acute renal and hepatic toxicity, evidenced by jaundice, elevated liver enzymes, azotemia, and changes in urinary function (polyuria, polydipsia). Central nervous system effects like seizures, lethargy, or ataxia are also officially noted in severe cases.

Overdose is classified as potentially leading to life-threatening outcomes, specifically gastrointestinal ulceration, acute renal failure, and acute hepatic toxicity, which have, in rare instances, resulted in death. The regulatory documents explicitly mandate immediate professional attention. A healthcare professional must be contacted without delay if ingestion above the labelled dose is suspected or if any adverse signs are observed. Accidental ingestion by a human also requires that medical advice be sought immediately.

The official labeling confirms that no specific antidote is known for Carprofen overdosage. Management is therefore limited to the application of general supportive therapy. Certain patient conditions, such as dehydration or pre-existing cardiovascular, renal, or hepatic dysfunction, are noted to increase the risk for severe renal toxicity.

Therapeutic Uses of Eurofen

The active substance in Eurofen is commonly used to help with symptoms related to inflammatory or irritative states, applied across domains where additional symptomatic support is needed. The agent is recognized for its relevance in easing symptomatic discomfort across various clinical settings.

The medication is commonly used across conditions presenting with acute episodes, providing symptomatic relief in situations involving osteoarthritis, degenerative joint disease, and postoperative pain following surgical procedures. It is applied across domains where additional symptomatic support is needed, primarily addressing the cluster of pain, swelling, and fever.

“Eurofen is relevant in contexts involving heightened systemic burden, assisting with maintaining functional stability.”

This usage generally contributes to improved comfort during periods of heightened symptoms or those in acute recovery phases. It helps address symptoms that may become disruptive over time or after a sudden event.


Quick Fact: Supportive Management for Pain, Swelling, and Fever

Eurofen may assist with maintaining functional stability when symptoms interfere with routine activities, contributing to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. NIH DailyMed Overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Eurofen

Eurofen (ibuprofen) is an established non-steroidal anti-inflammatory drug (NSAID) whose use is governed by formal regulatory guidelines defining who can and cannot take the medicine.

Populations for Whom Use is Prohibited (Contraindications)

Use of Eurofen is strictly contraindicated for individuals with a known hypersensitivity to ibuprofen, aspirin, or any other NSAIDs, including those who have experienced allergic reactions such as asthma, urticaria, or angioedema. It is also prohibited for patients with:

  • Active or a history of recurrent peptic ulcer/gastrointestinal (GI) haemorrhage.
  • Severe heart failure, renal failure, or hepatic failure.
  • The third trimester of pregnancy.
  • Right before or after coronary artery bypass graft (CABG) surgery.

Populations Requiring Special Consideration

Caution is required for use in the elderly and in patients with a history of GI disease (e.g., Crohn’s disease, ulcerative colitis) due to an increased risk of serious complications. Use is not recommended in patients with uncontrolled hypertension, established cardiovascular disease (e.g., NYHA II-III heart failure), or varicella (chickenpox). The lowest effective dose should be used for the shortest possible duration.

Age-Related Eligibility

Most common oral formulations are approved for use in adults and children geq 12 years of age. Specific pediatric liquid formulations may be eligible for children geq 3 months of age who weigh geq 5 kg; use in younger infants is typically contraindicated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation requires specific attention to certain categories of co-administered medicines and products due to potential pharmacokinetic (PK) interactions that alter Eurofen's plasma concentration.

Interacting Product Category Regulatory Constraint / Impact on Eurofen
Strong CYP3A4 Inhibitors (e.g., ketoconazole) Co-administration may significantly increase Eurofen's concentration in the body, which requires risk management.
Strong CYP3A4 Inducers (e.g., rifampicin, phenytoin) Co-administration may lead to significantly decreased Eurofen concentrations, risking potential therapeutic failure.
Other Enzyme/Transporter Substrates Co-use with other substrates of metabolizing enzymes (e.g., CYP2D6) or transport systems (e.g., P-gp) may alter the concentrations of either Eurofen or the co-administered medication.
Alcohol / Food Administration requirements related to food intake are specified to control clinically relevant changes in Eurofen's drug exposure, and potential interactions with alcohol are addressed.

These constraints mandate careful management of the concurrent use of Eurofen with medicines that strongly affect the cytochrome P450 3A4 enzyme pathway. Regulatory labels define circumstances where co-administration is restricted or requires mandatory monitoring to maintain appropriate drug exposure and efficacy.

Mechanism of Action

Core Mechanism: Inhibition of Cyclooxygenase

Eurofen operates as a reversible, non-selective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular action blocks the conversion of arachidonic acid into prostaglandin H2 ( PGH2), which is the precursor for the entire prostanoid family of signaling molecules.

Pathway Modulation and Physiological Consequence

The inhibition of COX directly interrupts the Arachidonic Acid Cascade, leading to a functional suppression of PGE2, PGI2, and TxA2 synthesis. This reduction in the concentration of these mediators exerts effects in both the peripheral systems and the central thermoregulatory center (hypothalamus). The system-level modulation results in a lowering of the hypothalamic temperature set-point, a reduction in nociceptor sensitization at peripheral nerve endings, and an attenuation of the local inflammatory vascular response through the limitation of pro-inflammatory mediator availability.

Dosage and Administration Information

Eurofen is characterized by defined administration pathways and dosing patterns. The medicine is supplied in forms suitable for oral ingestion as tablets or caplets (available in strengths such as 25 mg, 75 mg, and 100 mg), or as an injectable solution (50 mg/mL) for parenteral administration via the subcutaneous route. This duality provides options for both long-term at-home use and acute treatment in a clinical setting.

The dosage regimen is weight-based, utilizing a calculation of 4.4 mg per kilogram of body weight as the total daily dose. This dose can be administered either once daily or divided into two equal portions and given twice daily. For long-term use, protocols allow for a dose reduction to a lower maintenance level (e.g., 2 mg/kg) after an initial period, which involves ongoing veterinary supervision.

Key procedural conditions for use are identified for this medication. Oral forms may be administered with or without food, and tablets are often scored to facilitate weight-based dosing. The injectable solution is for subcutaneous administration only. If a dose is missed, standard practice is to avoid administering a double amount; treatment typically resumes with the next scheduled dose. Furthermore, special consideration and possible dose reduction are noted for administration to animals less than six weeks of age or aged populations.

Recent Clinical Evidence

Eurofen: Overview of Studies

Research Evidence for Use in Osteoarthritis and Degenerative Joint Disease

Research into Eurofen was studied for how it was observed in conditions characterized by fluctuating or episodic manifestations of discomfort, such as osteoarthritis and degenerative joint disease. These trials research examined outcomes related to physical discomfort, such as changes in pain intensity scores, and outcomes reflecting daily functioning or activity level. Studies reported how symptoms evolved in the observed populations related to discomfort levels over the specific study periods.

However, the primary evidence base and clinical trials used in research exploring how symptoms change over time are largely derived from veterinary clinical trials, particularly in dogs. Data for certain groups remain insufficient for general use in human populations with these conditions compared to the veterinary field.


Research Evidence for Use in Postoperative Pain Management

Eurofen was studied for outcomes related to physical discomfort during the recovery period following surgical procedures. These research scenarios typically involve short-term, acute-phase controlled trials. The studies monitored outcomes such as the severity of pain after surgery and the need for additional pain relief medications. This evidence is generally relevant in trials assessing short-term or episodic symptom patterns immediately following an acute event.

Follow-up durations were limited in this research, typically covering only the immediate post-operative period (e.g., 72 hours). There is limited information for long-term outcomes regarding its potential association with chronic pain development after surgery. The populations observed in these trials are heavily based on animal models, meaning the results apply only to the populations studied and do not offer direct insight into complex human protocols.


What is Still Uncertain About Eurofen's Evidence Base

The full context of the evidence highlights several areas where knowledge is incomplete. Evidence quality varies across studies, and the current research structure is heavily influenced by non-human clinical trials. Comparative evidence is lacking in terms of studies directly comparing Eurofen against a wide range of standard treatments for common human conditions.

The research provides context but not individual predictions. Certainty remains low for long-term outcomes, and the findings describe group patterns, not personal outcomes. This means that research does not determine whether an individual will respond similarly to the patterns observed in the studies.

Key Studies & References

  1. NIH DailyMed Drug Label Information: RIMADYL (Carprofen) Chewable Tablets
  2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Mechanisms of Action and Uses

Frequently Asked Questions (FAQ)

Common questions about Eurofen (FAQ)


Q: Does Eurofen interact with blood pressure medication?

A: Official regulatory information indicates that close observation is warranted when Eurofen is used with certain medications, including some drugs used to manage blood pressure (such as diuretics or ACE inhibitors). This is due to the potential for reduced effectiveness of the blood pressure medication and a potential for increased risk to the kidneys, as described in official warnings.


Q: Are there any food restrictions when taking Eurofen?

A: The official labeling for the oral form of Eurofen states that it may be administered with or without food. However, specific administration requirements are detailed in the full product information to manage the potential for clinically relevant changes in the drug’s absorption and exposure in the body.


Q: Is Eurofen a medication that needs to be taken long-term?

A: Official documentation describes protocols for long-term use, often involving a reduction to a lower maintenance dose after an initial period. However, the product safety information indicates that treatment extending over a long period is associated with a potentially higher likelihood of adverse reactions.


Q: Are there specific warnings for women who are pregnant or breastfeeding?

A: Official regulatory guidance indicates that the use of Eurofen is prohibited during the third trimester of pregnancy. For use during breastfeeding, the official safety information notes that a risk/benefit assessment is necessary due to the potential for the drug to be excreted in milk.


Q: Can Eurofen be used for chronic pain?

A: Research evidence and official labeling mention its use in managing symptoms associated with chronic conditions, specifically osteoarthritis and degenerative joint disease. These conditions are characterized by long-term, fluctuating episodes of discomfort, swelling, and reduced function.


Q: Is Eurofen suitable for vegetarians or people with allergies?

A: Official safety documents indicate that the use of Eurofen is prohibited for individuals with known hypersensitivity or allergic reactions to its active ingredient or other nonsteroidal anti-inflammatory drugs (NSAIDs). Information regarding the suitability of the formulation (e.g., excipients for specific diets) is found in the drug’s full list of ingredients.


Q: Can Eurofen be crushed or split?

A: The official documentation notes that Eurofen tablets are often scored, which typically relates to achieving weight-based dosing by dividing the tablet. Instructions regarding the crushing of the tablets for administration are not typically specified in the regulatory guidelines.


Q: What are the signs of a serious reaction to Eurofen?

A: Official warnings describe the potential for rare but serious adverse events, primarily affecting the gastrointestinal system, kidneys, and liver. These serious effects include conditions like ulceration, renal (kidney) failure, or hepatic (liver) toxicity, which are noted safety concerns in the regulatory information.


Q: Is Eurofen only used for short-term problems?

A: Regulatory evidence supports the administration of Eurofen for both short-term, acute relief, such as pain management following surgery, and in long-term regimens for chronic conditions like degenerative joint disease.


Q: Are there specific symptoms that mean Eurofen is working?

A: The medicine’s mechanism of action involves reducing the sensitivity of nerve endings and limiting the inflammatory response. This action is officially recognized for its ability to help manage physical discomfort, swelling, and elevated temperature.


Q: Does Eurofen cause drowsiness or make you sleepy?

A: Official side effect documentation for nonsteroidal anti-inflammatory drugs (NSAIDs) may list central nervous system effects such as drowsiness or lethargy. These are noted as possible adverse reactions in the official safety information.


Q: Are headaches a known side effect of Eurofen?

A: Headaches are a reported adverse reaction for nonsteroidal anti-inflammatory drugs (NSAIDs) and may be listed in the official safety information. These nervous system effects are noted as possible adverse reactions.


Q: Is it normal to feel a bit dizzy after taking Eurofen?

A: Dizziness or lightheadedness are adverse effects sometimes listed under nervous system disorders in the official safety documents. These are noted as possible effects within the official safety profile.


Q: How long does it usually take for Eurofen to start working?

A: Official documentation provides information on the time required for the drug's concentration to peak in the body. This measure is used to describe the expected onset of action for the medicine, and the timeframe may vary depending on the specific formulation taken.


Q: How long do the effects of Eurofen typically last?

A: Official documentation provides the half-life of the drug, which is the standard measure used to estimate the time required for a dose to be eliminated from the body. This information relates to the expected duration of effect for the medicine.


Q: Is Eurofen habit-forming or addictive?

A: Official regulatory labels define Eurofen’s class as a Nonsteroidal Anti-inflammatory Drug (NSAID). This class of medicine is typically not designated as a controlled substance by official government agencies.


Q: Do I need a prescription to get Eurofen?

A: The official regulatory classification specifies the product’s dispensing status. This classification indicates whether Eurofen is categorized as prescription-only (Rx) or whether it can be dispensed over-the-counter (OTC).


Q: Does Eurofen change my mood?

A: Official adverse reaction sections may list psychiatric effects that could potentially affect mood. These reported changes include symptoms such as agitation, confusion, or depression.


Q: Does Eurofen affect blood sugar levels?

A: Regulatory labels sometimes list metabolic effects, such as changes in blood glucose levels. Official documents may also include specific warnings about co-administration with other treatments for metabolic conditions.


Q: Is it true that Eurofen can cause skin sensitivity to the sun?

A: Photosensitivity, which is an increased skin sensitivity to the sun, is an adverse effect that has been reported for some nonsteroidal anti-inflammatory drugs (NSAIDs). This is sometimes listed in the official safety documents.


Q: Can Eurofen be taken with antacids?

A: Regulatory documents typically contain information regarding the effects of antacids. Since antacids can alter the absorption of Eurofen, the official instructions may address co-administration via specific guidance on administration timing.


Q: Does Eurofen affect contraceptive pills?

A: Drug labels usually include specific warnings regarding potential interactions with hormonal contraceptives. These warnings describe whether Eurofen is associated with effects on their efficacy.


Q: Is it common to have unusual dreams while taking Eurofen?

A: Unusual dreams or other sleep disturbances are a recognized adverse effect sometimes listed under psychiatric or nervous system disorders in official safety information.

How should Eurofen be stored and disposed of?

Eurofen (Carprofen) must be stored and handled according to its official formulation. Tablets typically require storage at controlled room temperature (e.g., 15 C to 30 C), whereas the injectable solution may require refrigeration (2 C to 8 C) before opening. The injectable solution must not be frozen and both forms must be protected from light and stored in the original, tightly closed container.

For the multi-dose injectable solution, official stability rules mandate that the product must be discarded 28 days after first opening. All forms must be securely kept out of the sight and reach of children and pets. Disposal of unused product should follow local regulations, often via a take-back program. It is prohibited to dispose of Eurofen in wastewater (drains).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eurofen found in:

A-Z Index: